



## **CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference**

ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 44<sup>th</sup> Annual Goldman Sachs Global Healthcare Conference being held from June 12<sup>th</sup>- 15<sup>th</sup>, 2023.

### **Fireside Chat**

Presenter: Sam Kulkarni, Ph.D., Chief Executive Officer

Date: Wednesday, June 14, 2023

Time: 10:00 a.m. PT

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at <https://crisprtx.gcs-web.com/events>. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

#### Investor Contact:

Susan Kim

+1-617-307-7503

[susan.kim@crisprtx.com](mailto:susan.kim@crisprtx.com)

#### Media Contact:

Rachel Eides

+1-617-315-4493

[rachel.eides@crisprtx.com](mailto:rachel.eides@crisprtx.com)



Source: CRISPR Therapeutics AG